Navigation Links
Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Date:9/8/2010

PARIS and TARRYTOWN, N.Y., Sept. 8 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns.  This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.  Both sanofi-aventis and Regeneron management and staff remain blinded to the interim study results.

"We look forward to the final results of the trial, which are expected in the second half of 2011 with belief that the combination of aflibercept and FOLFIRI has the potential to benefit patients with this difficult-to-treat disease," said Tal Zaks, Head of Development, Global Oncology Division, sanofi-aventis.

About the VELOUR StudyThe main objective of the VELOUR (Aflibercept Versus Placebo in Combination with Irinotecan and 5-FU [FOLFIRI] in the Treatment of Patients with Metastatic Colorectal Cancer after Failure of an Oxaliplatin Based Regimen) study is to evaluate the safety and effectiveness of aflibercept as a second-line treatment in combination with folinic acid (leucovorin), 5-fluorouracil, and irinotecan (FOLFIRI) in 1,226 patients with mCRC who previously had been treated with an oxaliplatin-based regimen.  The primary endpoint is improvement in overall survival.  Secondary endpoints include progression-free survival, response to treatment, and safety.

About the Aflibercept Clinical Development ProgramSanofi-aventis Oncology and Regeneron are collaborating on a broad oncology development program combining aflibercept (VEG
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
(Date:5/23/2013)... PARIS , May 23, 2013 ... (NYSE MKT: NSPR), the leader in embolic protection ... MASTER (MGuard for Acute ST Elevation Reperfusion) trial ... outperformed bare metal and drug eluting stents in ... (STEMI) patients.  Results from the trial were presented ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
(Date:5/23/2013)... Dr. Garber's Natural Solutions is ... now available at Whole Foods Laguna Niguel, 23932 Aliso ... of natural biotherapy formulas continues to expand its' presence ... Brandstorm HBC (Los Angeles, CA), the line of remedies ... and Arizona, as well as Lassen's Markets in California, ...
(Date:5/23/2013)... May 23, 2013 On May 23, Voices ... and advocacy, commends Salem High School senior Max Merget for ... , According to a Patch.com article, Max Merget ... anaplastic ependymoma -- a large malignant tumor in the dominant, ... underwent surgery but the tumor came back a year later ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Brad Schmett, ... announced that the already sizzling Palm Springs area ... thanks to the immense popularity of the Annual Memorial ... on Monday, May 27, 2013. , Culminating the festive ... of programs and events along with flight exhibitions. However, ...
(Date:5/23/2013)... May 23, 2013 After working continuously ... beta testing regimes, Shopping Cart Elite officially ... Redsandmotorsports.com is an Arizona based online store retailing in ... , “Addition of new stores to our clientele has ... Cart Elite, Igor Soshkin. “We are extremely elated with ...
(Date:5/23/2013)... Texas (PRWEB) May 23, 2013 ... their daily routines, Walkingspree is pleased to announce ... with Fitbit pedometer devices. This new upgrade automatically ... dashboard members use to track their company’s team ... chart calories and fat burned. , Walkingspree also ...
Breaking Medicine News(10 mins):Health News:Dr. Garber's Natural Solutions Now Available at Whole Foods Market, Laguna Niguel, CA 2Health News:Voices Against Brain Cancer Commends Young Man for Raising Money for Brain Cancer Despite Fighting His Own Battle 2Health News:Annual Memorial Day Flower Drop Honors Veterans in Palm Springs California by Brad Schmett 2Health News:Shopping Cart Software Provider, Shopping Cart Elite Officially Announces the Launch Of Redsandmotorsports.com 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 2Health News:Walkingspree Expands Device Options with Fitbit to Increase Member Engagement in Corporate Wellness Programs 3
... Va., Sept. 30 Military Officers Association ... Jr., USN (Ret), pulled no punches in expressing MOAA,s ... raising hospital inpatient copays by $110 per day for retired ... "We,re shocked and extremely disappointed that there would be any ...
... Anchor Bay Entertainment, the successful distributor of independent ... with Susan G. Komen for the Cure(®) in the ... months, Anchor Bay Entertainment will donate $1 for each ... well as develop specialized promotions for the campaign to ...
... ... AllerQuest, LLC, are pleased to announce the return of PRE-PEN® penicillin allergy skin testing ... has entered into a definitive agreement with AllerQuest to market and distribute PRE-PEN®. ... Round Rock, TX ...
... benefit when therapy goes to more than just severe ... -- Pregnant women who receive treatment for the mildest ... intervention, self-monitoring of blood glucose levels and possibly insulin ... complications or develop preeclampsia or high blood pressure during ...
... ... Investor and New England Patriots President Jonathan Kraft , ... Boston, MA (Vocus) September 30, 2009 -- The Boston biotechnology industry ... Boston Biotech R&D Conference on October 27, 2009 at Harvard Medical School. , , ...
... Sept. 30 Most American children don,t see their family ... later than is recommended by both dental and medical professionals. ... of American children,s oral health, conducted on behalf of Delta ... Dental commissioned the survey to gain greater knowledge about the ...
Cached Medicine News:Health News:MOAA Decries 21% TRICARE Inpatient Copay Hike 2Health News:Anchor Bay Entertainment Joins Forces With Susan G. Komen for the Cure(R) in the Fight Against Breast Cancer 2Health News:Anchor Bay Entertainment Joins Forces With Susan G. Komen for the Cure(R) in the Fight Against Breast Cancer 3Health News:FDA Approves PRE-PEN Penicillin Allergy Test 2Health News:Study Urges Treatment for Even Mild Gestational Diabetes 2Health News:Study Urges Treatment for Even Mild Gestational Diabetes 3Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Health News:Delayed First Visit to Dentist Can Affect Children's Lifelong Oral Health 2
... (TSH) is a 32 kDa glycoprotein secreted ... pituitary gland [1]. The structure of human ... pituitary and placental gonadotropins, consisting of an ... these hormones and a unique beta-subunit, which ...
... Thyroxine (T4) is the primary active hormone ... thyroid gland [1]. T4 is synthesized via ... trapping by the follicular cells, (ii) iodination ... leading to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine ...
... is produced primarily by 5-monodeioination of thyroxine ... gland, T3 production occurs at a rate ... T4. Release of T3 from the thyroid ... as compared to 80-100 micrograms/day for T4. ...
... Insulin-like growth factor binding protein-3 (IGFBP-3) is the ... postnatal serum, as a component of the ~150 ... a molecule of IGF-I or IGF-II and ALS, ... actions of the IGFs. The molar concentration of ...
Medicine Products: